Member Info for potnak

Yep, defo setsqx. I think as joint brokers, Sareums registered MM's are Strand Hanson and Peel Hunt but if volume picked up, more would join to facilitate the market.

https://www.londonstockexchange.com/stock/SAR/sareum-holdings-plc/company-page

Hey nav, sort of what I said but depends on whether the stock has assigned Mm's.

https://www.londonstockexchange.com/equities-trading/asset-classes/shares-trading/setsqx-and-seaq

I don't really understand it myself, but the image of an MM watching screens and deciding where to set the price just doesn't happen on AIM stock. I suspect there is some sort of flag on the system when high volume or big orders are placed, and a human takes over. IMO, the brokers who do MM work like to perpetuate the old fallacies, when most of the time it's just a computer matching trades.

NAV, it's a setsqx stock. Partial electronic order book with MM intervention if orders can't be matched. I think that's how it works. Auctions at 8 9 and 11 and a couple on the afternoon. Usually when posters here say they can't buy, or are getting NT, its auction time. That's why most posts about the Mm's are rubbish. They only really come into play on big volume or when it's illiquid.

Exactly, HBD. He will have seen the full 737 data. I submitted a question at the last IM call. Specifically around 737 in Combo with ADC's. JR answered roughly saying he would love to talk to any pharma re ADC/Combo. Weirdly the Q&A answers aren't there now. They were a couple of weeks ago but it's on the presentation video. GSK's offering is an ADC and if there is a risk that 737 in combo might take some of the potential HGSOC market then they might go for 737 to eliminate the competition, with a view to triple combo it.

Might not make a difference Utar but 2 bit of news, regarding HGSOC and Hydroxyurea + combo in the same week, Coincidence? In terms of development, 737 isn't that far behind Mo-rez and with Hydroxyurea being off patent and already Approved. A small phase 2 trial to show efficacy and away they go. Plus 737 is in capsule form, it's doesnt need a visit to hospital for dosing. I think that could be something.

I don't have enough knowledge for this but I think this makes 737 a GSK target and a trigger for a bidding war. hydroxyurea and mo-rez might benefit from something that stops the tumor repair itself (737). If that was the case, GSK could dominate the HGSOC market. You can bet that the likes of Astra will be watching this unfold.

Also - the nature article and this dropping in the same week is a convenient coincidence. Like it was planned.

Just for fun. AI thinks a HGSOC compound could be worth between 500 million and 1.2 billion dollars for a licence deal with a 30 to 100 million dollars upfront. With GSK as the favourite (because, they've already seen 737)

good to see they posted this. the publication mentions sierra still so either the author wasn't aware or the tests were done while the compound was still under sierras umbrella.

the below sounds good and as i stated earlier. sareum are ready to go.

"chk1i+ldhu effectively killed ovarian cancer cells regardless of prior chemotherapy responses, brca2 mutation and ****logous recombination repair status in vitro. in vivo, treatment significantly reduced tumour burden and ascites accumulation. chk1i+ldhu enhanced expression of pro-inflammatory cytokines/chemokines and triggered immunogenic cell death in tumour"

i've been trying to do a bit of research as to who might have a hgsoc hole in their pipeline and it appears to be most pharma.

Hi Laz, my own personal thoughts are. My holding has never had so much potential and risk at the same time. Schrödinger's biotech, if you like. Where we don't know if it is a multibagger or total loss, until we look in the box.

If the Tox study concludes with a good outcome. Then we have a phase 2 ready TYK2 immunotherapy compound, A phase 1 ready TYK2 cancer compound. A literal, phase 2 ready CHK1 and by literal, I mean ind status ready and enough manufactured compound to run a trial!

Success or movement on any of the above changes the game here

And we a possible CNS compound that will hopefully cross the BBB.

In the 15 years I have been here, there has never been so much potential resting on one little trial.

Something has to give in the next 8 weeks.

Should be in week 8 now, Celtic.

IMO. This article deserves some acknowledgement from Sareum. A tweet at the very least. There are some big players in the DDR landscape and Sareum have a phase 2 ready DDR compound, with enough of the compound in stock to go a combo trial with LDHU ASAP. With Ovarian cancer being notoriously difficult to to treat. Could fast track status be given?

The COVID bubble was the perfect storm. It's hindsight now but an undervalued biotech minnow that just happened to be developing compounds that could treat the cytokine storms that COVID was causing. Combine that with a few HNWI deciding to invest heavily and a lot of furloughed ,dumb money in the market and it was the perfect storm. The truth was slightly different. 1801 was maybe 2 to 3 years away from being a genuine contender. No one's fault, COVID and SDC1801 were on different timelines but as the dust settled on the COVID casino, it was pretty clear how far off we actually were. However. The value and market cap we reached was probably accurate and id expect a phase 2 ready compound should be heading to those sorts of values again. Especially if the studies validates the other TYK2 compounds.

The biggest barrier to value creation right now is sentiment. The LTH, if averaged down, shouldn't be far off break even but for others, they are massively under water or have taken the hit and sold out. Future investors are going to need more certainty before they come back and that means milestones reached. Tox study complete, a deal in the bag or both!

Yep, this time next week and we should be half way through the dosing period.

Not sure if anyone has seen them but the QandA answers are on the IM site.

SAREUM HOLDINGS PLC - Unaudited financial results for the six months ended 31 December 2025 | Investor Meet Company https://share.google/YXWxoQTbkb6McPfoz

I don't calculate future value on currents shares in issue. I work on the 156 million shares if all Warrants are exercised. But we know some run out this summer so if not taken. Then, even with a raise (at the right price) the 156 million might not change that much. Set any future warrants above £2 and id be happy with that.

Yep, this paragraph

At current burn rates, we expect Sareum to be funded into H2 CY26 with sufficient liquidity to complete the toxicology study. Additional capital will be required in H2 ahead of partnering decisions for SDC-1801, with potential licensing revenues from SDC-1802 and SRA737 providing non-dilutive support.

I reckon the roadshow stuff today is looking to put feelers out in case they need to secure funding. We know it's going to be tight. Better to have a plan B in our back pocket.

Nice Title! Almost like Ahfam's year of the rerate.

Johnson and Johnson rang a bell. So I asked my little AI friend to elaborate on the TuHURA scenario. Yep, it's a sierra link.

The 2018 Janssen Supply Agreement

​In early 2018, Sierra Oncology officially signed a clinical supply agreement with Janssen Research & Development, LLC.

​The Deal: Under this agreement, Janssen agreed to supply Sierra Oncology with their blockbuster PARP inhibitor, Zejula (niraparib).

​The Goal: The drugs were supplied specifically to facilitate a planned Phase 1b/2 clinical trial combining SRA737 + Zejula.

​The Target Indication: The trial was aimed at treating metastatic castration-resistant prostate cancer (mCRPC). (Note: While Tesaro/GSK originally developed niraparib, Janssen holds the exclusive global rights to the drug specifically for prostate cancer, which is why the deal was struck with J&J).

​The Scientific Rationale (Why J&J agreed to it)

​Janssen didn't just hand over their drug blindly; they agreed to the partnership because the science behind combining a PARP inhibitor with a Chk1 inhibitor is incredibly strong.

​PARP inhibitors (like Zejula) stop cancer cells from repairing single-strand DNA breaks.

​Chk1 inhibitors (like SRA737) stop the cells from pausing their cell cycle to fix the damage, forcing them to replicate with broken DNA, which causes the cancer cell to self-destruct (apoptosis).

​Combining the two creates a profound "synthetic lethality."

​What This Means for Sareum Today

​While Sierra Oncology was eventually acquired by GSK (primarily for a different blood cancer drug) and the rights to SRA737 were returned to Sareum, this historical J&J link is a massive strategic advantage for Tim Mitchell right now:

​Prior Due Diligence: J&J’s oncology and partnering teams have already evaluated SRA737’s preclinical data and mechanism of action. They liked it enough in 2018 to attach their own multi-billion-pound drug to it. SRA737 is a "known entity" to their scientists.

​The PARP Synergy: Big Pharma companies with PARP inhibitors are currently desperately looking for combination partners to overcome "PARP resistance" in patients. J&J already knows SRA737 is a viable candidate for this.